TY - CHAP
T1 - New biomarkers in non-Hodgkin lymphoma and acute leukemias
AU - Rubio-Jurado, Benjamín
AU - Sosa-Quintero, Lluvia Sugey
AU - Carrasco-Martinez, Ivette Lenina
AU - Norato-Delgado, Armando
AU - Garcia-Luna, Eduardo
AU - Guzmán-Silahua, Sandra
AU - Riebeling-Navarro, Carlos
AU - Nava-Zavala, Arnulfo Hernan
PY - 2020
Y1 - 2020
N2 - Biomarkers play a critical role in the medical care of patients with cancer, including in early detection of the disease, diagnostic accuracy, risk stratification, treatment, and follow-up. Biomarkers in hematological malignancies can support the redefinition of the diagnosis and adjustments in the treatment plan. Biomarkers can be classified into 4 categories: (1) protein antigens, (2) cytogenetic abnormalities, (3) genetic polymorphisms, and (4) gene expression. Efforts in genomics, proteomics, and metabolomics to observe new biomarkers that contribute to the development of clinical medicine with greater precision in the strategies that improve prevention, diagnosis, and treatment of patients with malignant hematological disease. New biomarkers should accomplish several issues such as the biological plausibility, methodology used, analytical validation, intellectual property registry, and legal framework of application. This knowledge should be transferred to health professionals who can carry out the process of its implementation in clinical practice.
AB - Biomarkers play a critical role in the medical care of patients with cancer, including in early detection of the disease, diagnostic accuracy, risk stratification, treatment, and follow-up. Biomarkers in hematological malignancies can support the redefinition of the diagnosis and adjustments in the treatment plan. Biomarkers can be classified into 4 categories: (1) protein antigens, (2) cytogenetic abnormalities, (3) genetic polymorphisms, and (4) gene expression. Efforts in genomics, proteomics, and metabolomics to observe new biomarkers that contribute to the development of clinical medicine with greater precision in the strategies that improve prevention, diagnosis, and treatment of patients with malignant hematological disease. New biomarkers should accomplish several issues such as the biological plausibility, methodology used, analytical validation, intellectual property registry, and legal framework of application. This knowledge should be transferred to health professionals who can carry out the process of its implementation in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85081289652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081289652&partnerID=8YFLogxK
U2 - 10.1016/bs.acc.2019.11.002
DO - 10.1016/bs.acc.2019.11.002
M3 - Chapter
AN - SCOPUS:85081289652
SN - 9780128211663
T3 - Advances in Clinical Chemistry
SP - 19
EP - 53
BT - Advances in Clinical Chemistry
A2 - Makowski, Gregory S.
PB - Academic Press Inc.
ER -